NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

Similar documents
NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

Hyperglycemia Procedure: Management and Treatment Adult Patients

Glycemic Management Hypoglycemic & Hyperglycemic Treatment Continuing Care

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

P R O J E C T B U L L E T I N - F A L L I N T H I S I S S U E U P D A T E S F O R

Provincial Clinical Knowledge Topic Insulin Pump Therapy, Pediatric and Adult Acute Care V 1.0

How to BBIT An Educational Resource for Prescribers AHS Adult Subcutaneous Basal Bolus Insulin Therapy (BBIT)

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

Basal Bolus Insulin Therapy (BBIT) and improved glycemic management in hospital

Basal Bolus Insulin Therapy Frequently Asked Questions

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

Diabetes Management in New Brunswick Nursing Homes

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool

In-hospital management of diabetes

In - Hospital Diabetes Care. A review and personal experience

Calgary Diabetes Centre Insulin Pump Therapy: Preparation and Expectations

New Hires Program Canadian Diabetes Educator Certification Board Competencies Addressed

Oral and Injectable Non-insulin Antihyperglycemic Agents

Common Drug Review Patient Group Input Submissions

The principles of insulin adjustment guidance

Hypoglycemia, Sick Days/DKA and Hospitalization

HYPOGLYCEMIA: Prevention, Recognition and Treatment in Residential and Acute Care Self Learning Plan

Pharmacy Plan Guidance

Calgary Diabetes Centre Insulin Pump Therapy: Preparation and Expectations

COMPLIANCE WITH THIS DOCUMENT IS MANDATORY

APPENDIX American Diabetes Association. Published online at

Section 504 Plan (sample)

Special Situations 1

PERIOPERATIVE DIABETES GUIDELINE

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

The most recent estimates suggest that. A study of inpatient diabetes care on medical wards. Saqib Javed, Yaser Javed, Kate Barnabas, Kalpana Kaushal

Physical Activity/Exercise Prescription with Diabetes

Lynda Astbury Lead Diabetes Specialist Nurse

Prior to making any insulin adjustments the following knowledge and skills are required:

A Children s Bedtime Story

This certificate-level program is non-sponsored.

GESTATIONAL DIABETES (DIET/INSULIN/ METFORMIN) CARE OF WOMEN IN BIRTHING SUITE

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

Common Drug Review Patient Group Input Submissions

Peri-operative management of the surgical patient with diabetes GL059

Management of Women with Type I Diabetes or Insulin Treated Type II Diabetes

My Sick Day Plan for Type 1 Diabetes on Multiple Daily Injections (MDI)

Complete Comprehensive Diabetes Educator modules available at CCCEP File #: I-P (Expires: Mar.

Guideline for Children with Type 1 or Type 2 Diabetes on Insulin Requiring Surgery or Sedation

Dept of Diabetes Main Desk

DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address:

TYPE 1 DIABETES MELLITIS CARE OF WOMEN IN BIRTHING SUITE

Starting and Helping People with Type 2 Diabetes on Insulin

Continuous Subcutaneous Insulin Infusion (CSII) pump therapy

FREEHOLD REGIONAL HIGH SCHOOL DISTRICT. Parents/Guardian of

Welcome Everyone. Monitoring, Sick Days, Inpatient Management - Objectives. Mrs. Jones has new diabetes. She asks you: Page 1

Diabetes Labour guideline (GL820)

Diabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust

Injectable Therapies in Diabetes

The Many Faces of T2DM in Long-term Care Facilities

Pump Failure Guidelines

Diabetes Medical Management Plan

Diabetes Emergency Caesarean section or other unplanned surgery (GL822)

What s new in diabetes care? Connect and Learn April 13, 2018 Tess Montada-Atin NP-Adult, CDE

Please inform the Diabetes Nurse Specialist that this patient has been admitted within 24hrs of admission.

123 Are You Providing Evidence-Based Diabetes Care? - Martin

PARENT PACKET - DIABETES

SHINE Study PowerChart Order Set CONTROL

Executive Summary Management of Type 1 Diabetes Mellitus during illness in children and young people under 18 years (Sick Day Rules)

DKA : Diabetic Ketoacidosis & HHS: Hyperlgycemic Hyperosmolar Syndrome Protocol. Glycemic Task Force September 2014

Glycemic Control IU Health Diabetes Centers

CHAPTER NINE INSULIN AND GLUCAGON ADMINISTRATION

Guidelines for the Management of Diabetic Ketoacidosis (DKA) in Adults Inpatient Diabetes Steering Group

MANAGEMENT OF PREGNANT WOMEN WITH DIABETES WHO ARE IN-PATIENTS IN THE ROYAL INFIRMARY

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

MONMOUTH COUNTY VOCATIONAL SCHOOLS

Rancocas Valley Regional High School Diabetes Medical Management Plan

Objectives. Why is blood glucose important? Hypoglycaemia. Hyperglycaemia. Acute Diabetes Emergencies (DKA,HONK)

Insulin Order Sets & In-Hospital Management of Diabetes

DIABETES MEDICAL MANAGEMENT PLAN (DMMP) School Year: Student s Name: Date of Birth:

SARASOTA MEMORIAL HOSPITAL

Date of Diabetes diagnosis Type I Type II. School Nurse Phone. Mother/Guardian. Address. Home phone Work Cell. Father/Guardian.

Diabetes in obstetric patients

National Diabetes Inpatient Audit (NaDIA) 2016

Supplemental Health Record and Authorization for Care of Child with Insulin Dependent Diabetes

for school staff Developed for Chicago Public Schools by: LaRabida Children s Hospital and Children s Memorial Hospital November 18, 2011

Care of Students with Diabetes

DIABETES AND PREGNANCY. CDE Exam Preparation March 22 & 27, 2018 Presented by Wendy Graham RD CDE Mentor

Guide to Starting and Adjusting Insulin for Type 2 Diabetes*

Date of birth: Type 2 Other: Parent/guardian 1: Address: Telephone: Home: Work: Cell: address: Camper physician / health care provider:

Index. Note: Page numbers of article titles are in boldface type.

GLYXAMBI (empagliflozin-linagliptin) oral tablet

Learning Objectives. Perioperative SWEET Success

Objectives. Why is blood glucose important? Hypoglycaemia. Hyperglycaemia. Acute Diabetes Emergencies (DKA,HONK)

Diabetes Medical Management Plan

PHYSICIAN S ORDERS Page 1 of 1 Providence Hospital ICU Insulin Drip Protocol

International School Bangkok Diabetes Management Plan 2018/19

Diabetes Medical Management Plan/Individualized Healthcare Plan. Part A: Contact Information must be completed by the parent/guardian.

NOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING

Diabetes in Pregnancy

Guidelines for the Safe Management of Insulin Pump Therapy in Hospital. Diabetes Obesity Nutrition Strategic Clinical Network

Transcription:

TITLE GLYCEMIC MANAGEMENT - ADULT SCOPE Provincial: Acute Care APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Diabetes, Obesity & Nutrition Strategic Clinical Network PARENT DOCUMENT TITLE, TYPE AND NUMBER Not applicable DOCUMENT # HCS-206 INITIAL EFFECTIVE DATE September 1, 2017 REVISION EFFECTIVE DATE October 27, 2017 SCHEDULED REVIEW DATE September 01, 2020 NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section. If you have any questions or comments regarding the information in this document, please contact the Policy & Forms Department at policy@ahs.ca. The Policy & Forms website is the official source of current approved policies, procedures, directives, standards, protocols and guidelines. OBJECTIVE To outline expectations and recommended strategies for glycemic management of adult patients presenting to or admitted to an Alberta Health Services (AHS) Acute Care setting. PRINCIPLES Glycemic management is required to support patients to meet their blood glucose targets, prevent exacerbation of acute illness, promote wound healing, prevent infections and avoid other complications. Appropriate glycemic management supports a smooth transition into hospital for patients with diabetes. It also supports a smooth transition out of hospital, and back into the community. Attention to recommended blood glucose targets in hospital is consistent with how patients are taught to manage their diabetes in the community. Maintaining blood glucose within the recommended targets is necessary to ensure safety for patients, and mitigate the immediate risks associated with hypoglycemia. It is also necessary to decrease the risks associated with hyperglycemia including delayed wound healing, hospital acquired infections, mortality, increased length of hospital stay, and other complications. APPLICABILITY Compliance with this document is required by all Alberta Health Services employees, members of the medical and midwifery staffs, Students, Volunteers, and other persons acting on behalf of Alberta Health Services (including contracted service providers as necessary) working in Acute Care settings. Alberta Health Services (AHS) PAGE: 1 OF 6

ELEMENTS 1. Points of Emphasis 1.1 For the purposes of this policy suite only, Acute Care setting includes all AHS urban and rural hospitals (including the Emergency Department), psychiatric facilities, and Urgent Care facilities. 1.2 This document may be used in non-acute care settings. Site/unit managers are responsible for determining whether this document in whole or in part is appropriate to their patient care setting and communicating that out to staff. 2. Blood Glucose Target Ranges 2.1 For the majority of non-critically ill patients, random blood glucose should be in the target range of five (5) ten (10) millimoles per litre (mmol/l). a) Exceptions include, but may not be limited to: Diabetes in pregnancy (where the individualized target range may be modestly lower); patients with a guarded diagnosis (i.e., end of life); those who have been identified to have hypoglycemia unawareness; the frail elderly; and patients with multiple co-morbidities (where the individualized target range may be modestly higher). 2.2 For critically ill patients blood glucose target range is eight (8) ten (10) mmol/l. 2.3 For frail elderly patients blood glucose target range is five (5) 12 mmol/l. 2.4 For patients whose blood glucose is anticipated to be outside of the recommended range, the most responsible health practitioner should identify the target range on the patient's chart. 3. Glycemic Management Strategies 3.1 Meeting glycemic targets requires a multidisciplinary approach, which involves an array of strategies. 3.2 Appropriate blood glucose monitoring of patients with a known history of diabetes, newly diagnosed with diabetes, or an elevated blood glucose shall be performed: a) Minimum of four (4) times a day (QID) and as needed (prn), for acutely ill patients and patients receiving insulin; b) patient specific testing regime in consultation with the health care team if the patient s blood glucose is stable and well controlled, and they are not acutely ill (e.g., patients awaiting alternate level of care); Alberta Health Services (AHS) PAGE: 2 OF 6

c) patient specific testing regime in consultation with the health care team for patients with diabetes in pregnancy (antepartum as well as labour and delivery); d) more frequent monitoring (hourly or every two (2) hours) for patients receiving intravenous insulin; e) PRN testing may be indicated (prior to the patient leaving the Unit) when the patient will be off Unit at a location where blood glucose testing is not readily available, and/or the patient will be engaging in physical activity; f) Include patient self-management and/or self-monitoring, in addition to in hospital point of care testing, where appropriate. 3.3 Appropriate blood glucose monitoring of patients without diabetes that are prescribed and taking medications known to cause hyperglycemia (i.e., steroids) shall be performed: a) minimum of two (2) times a day (BID) at lunch and supper scheduled meal times; and b) minimum of four (4) times a day (QID) if hyperglycemia present. 3.4 Capillary blood is not recommended for blood glucose testing for patients with severely impaired peripheral circulation (e.g., hypovolemia, shock). 3.5 Appropriate subcutaneous (SC) insulin prescription: a) Insulin is the most appropriate agent for effectively controlling hyperglycemia in hospital, including when oral agents are not safe or effective for patients with Type 2 diabetes. b) A proactive approach using scheduled basal, bolus, and correction (supplemental) insulin regime is the preferred method. c) Sliding scale insulin alone should be avoided in preference of a basal bolus insulin regime, to improve patient outcomes. 3.6 Timing of insulin administration should be coordinated with meals and blood glucose testing. a) Blood glucose testing should be done within 30 minutes prior to meal; and b) Insulin should be administered based on this test no more than 30 minutes prior to meals in most instances. (i) (ii) Short acting insulin should be given 30 minutes prior to a meal; and Rapid acting insulin should be given just before a meal. Alberta Health Services (AHS) PAGE: 3 OF 6

(iii) Meal/bolus insulin may be given immediately after the meal/feed in certain situations (e.g., gastroparesis or concern that the patient may not be able to ingest or retain the full meal). c) Consideration of the effects of other anti-hyperglycemic medication may also be necessary when timing meals and blood glucose testing. 3.7 For patients with insulin pump therapy (IPT); if the insulin pump is stopped, basal insulin must be replaced within two (2) hours to prevent diabetic ketoacidosis (DKA). Severe hyperglycemia and/or DKA can result when IPT is stopped for as little as two (2) to four(4)_hours and the insulin is not replaced; even if blood glucose values are normal or low when the pump is discontinued. 3.8 Appropriate assessment and treatment of asymptomatic and symptomatic hypoglycemia (most often drug induced from insulin or insulin secretagogues) includes, but may not be limited to: a) Early recognition; b) treatment for all patients with a blood glucose less than four (4) mmol/l, even those asymptomatic; c) avoiding overtreatment of hypoglycemia to prevent rebound hyperglycemia; (i) 15 grams of fast-acting carbohydrates is usually sufficient for managing hypoglycemia for patients who are able to have oral intake.(e.g., four (4) dextrose tablets or 3/4 cup of juice). d) Decreasing insulin doses rather than holding or discontinuing to promote glycemic management; and e) contacting the most responsible health practitioner when indicated, as per AHS Treatment of Hypoglycemia Procedure. 3.9 Appropriate assessment and treatment of hyperglycemia includes, but may not be limited to: a) Contacting the most responsible health practitioner for further orders, when the patient s blood glucose is greater than 18 mmol/l and/or when otherwise indicated in the AHS Treatment of Hyperglycemia Procedure; b) stat ketone testing is recommended: (i) (ii) For patients with Type 1 diabetes when blood glucose is greater than 18 mmol/l; for patients on insulin pump therapy when blood glucose is greater than 14 mmol/l; or Alberta Health Services (AHS) PAGE: 4 OF 6

(iii) for patients on Sodium-glucose co-transporter two (2) (SGLT2) inhibitors when blood glucose is greater than 14 mmol/l or who display symptoms of diabetic ketoacidosis (DKA). SGLT2 inhibitor medications include: canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance). DEFINITIONS c) assessing for DKA if patient with Type 1 diabetes is displaying signs of DKA and/or if unable to decrease patient s blood glucose. 3.10 Unless otherwise indicated, patients with diabetes should receive a diabetic diet that provides meals and snacks to promote glycemic control. 3.11 Patients with diabetes should be in safe blood glucose range before physical activity or exercise. 3.12 Patients should not be sent off Unit, especially for physical activity, when their blood glucose is less than four (4) mmol/l. 3.13 Patients should not be sent off Unit, especially for physical activity, when their blood glucose is greater than 18 mmol/l without approval from the most responsible health practitioner. 3.14 Newly diagnosed patients (with diabetes) or those with unstable blood glucose levels, should be referred to a Certified Diabetes Educator (CDE) or diabetes specialist, when available. Most responsible health practitioner means the health practitioner who has responsibility and accountability for the specific treatment/procedure(s) provided to a patient and who is authorized by Alberta Health Services to perform the duties required to fulfill the delivery of such a treatment/procedure(s), within the scope of their practice. Patient for the purposes of this policy means an adult who receives or has requested health care or services from Alberta Health Services and its health services providers or individuals authorized to act on behalf of Alberta Health Services. Alberta Health Services (AHS) PAGE: 5 OF 6

References Alberta Health Services Governance Documents: o Treatment of Hypoglycemia Procedure (HCS-206-01) o Treatment of Hyperglycemia Procedure (HCS-206-02) o Point of Care Testing (POCT) Policy (PS-90) Non-Alberta Health Services Documents: o Canadian Diabetes Association 2013 Clinical Practice Guidelines VERSION HISTORY Date October 27, 2017 Action Taken Revised Alberta Health Services (AHS) PAGE: 6 OF 6